Safety of Dose Escalation for Pancreatic Cancer Using a Uni-Directional, Pd-103 Implantable Radiation Device: Results of a Phase I Trial.

J. E. Meyer,D. Wang,S. S. Reddy,D. A. Todor, A. Amini,E. C. Fields,R. A. Price, J. L. Gnerlich, S. E. Sckolnik, E. Smith, B. Kaplan, E. L. Zakris, R. Sanford,J. V. Turian, P. D. Crossan, M. G. Mesleh, R. P. Laureckas

International journal of radiation oncology, biology, physics（2021）

引用 0|浏览20

暂无评分

摘要

Patients tolerated the device well with only one adverse event possibly related to study treatment. A MTD of 35 Gy EQD2 was determined to be safe for this patient population and is being prescribed in the phase II portion of the study. The permanently implantable, uni-directional, Pd-103 device delivers a targeted dose boost to the surgical margin in this difficult to treat patient population. The ongoing phase II protocol is currently enrolling additional subjects to evaluate local control at 1 year.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要